![Uuid generator online](https://loka.nahovitsyn.com/212.jpg)
![nightingale home health nightingale home health](https://s3.amazonaws.com/www.homehealthcareagencies.com/images/uploaded/10002.large.jpg)
The new shares to be used in the acquisition are subject to lock-up provisions, which will terminate for Yolife’s founders if certain revenue milestones are met while the financial investors are bound by the same lock-up period as Nightingale’s shareholders (180 days from the IPO, 19 March 2021).
#Nightingale home health series#
As a result of the subscriptions, the number of shares in Nightingale will increase to 60,609,633, including Series A, Series B and EMP shares. The new shares are expected to be admitted to trading on Nasdaq First North Growth Market on 13 July 2021. The new shares are expected to be registered in the Trade Register on 12 July 2021, as of which date the new shares will establish shareholder rights. The directed issue comprises of 80,179 new Series B shares in Nightingale, which correspond to approximately 0.1 per cent of all Nightingale shares prior to the directed share issue. The parties have agreed that the total purchase price of Yolife’s shares is approximately EUR 740,000, of which approximately 30 per cent will be paid in cash consideration, while 70 per cent will be covered by a directed share issue of Nightingale’s Series B shares with a subscription price of EUR 6.75 per share. The acquired capabilities that will be integrated will increase Nightingale’s annual operative costs by approximately EUR 350,000. Nightingale will integrate Yolife’s capabilities as part of Nightingale’s business and does not expect Yolife’s current business to create revenue. Yolife is an early-stage technology and service company founded in 2019, with no equity or significant revenue or debt (less than EUR 100,000). The acquisition of Yolife strengthens Nightingale’s digital health capabilities and together w ith the earlier announced partnership with Weavr Health Nightingale aims to have a strong and rapidly growing launch of its at-home testing solution in the first half of 2022. The coming new mobile application will integrate Nightingale’s leading biotechnology with digital health capabilities.įurthermore, Nightingale expects the acquisition of Yolife to s upport the launch of Nightingale’s at-home testing solution for consumers and business partners. The Yolife acquisition, the strategic Reaktor partnership and Nightingale’s in-house high-performance team together enable Nightingale to launch a globally competitive mobile application version in the near term. The acquisition is expected to substantially support the development of Nightingale’s digital health capabilities particularly in the direct-to-consumer market. The assets of Yolife will be integrated into Nightingale’s preventative health offering and the founding team of Yolife will join Nightingale to accelerate Nightingale’s mission to deliver preventative health solutions globally. The Yolife digital health solution learns from the user’s behavior and provides the user with a holistic wellbeing strategy made of challenges that motivate and help the user to achieve their health goals. Nightingale ’s proprietary biotechnology platform provide s a holistic health analysis from a single blood sample that no other technology in the market can match. The key competitive advantage in the global health and wellness market is the ability to combine biotechnology and digital health. Yolife is a German digital health company that has created a mobile application helping everyone to live longer in good health through science-based lifestyle changes.
![nightingale home health nightingale home health](https://2.bp.blogspot.com/-jiGIqGbfkzY/Vq-fD5pLP6I/AAAAAAAAAGw/6FQj8r7IVOY/s320/dreamstime_m_7060672%2B%25282%2529.jpg)
It does not store any personal data.Nightingale Health Plc’s (”Nightingale”) world-leading b lood testing platform is complemented with Yolife GmbH’s (”Yolife”) digital health capabilities in an acquisition where Nightingale acquires all shares of Yolife. The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. The cookie is used to store the user consent for the cookies in the category "Performance". This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". The cookie is used to store the user consent for the cookies in the category "Other.
![nightingale home health nightingale home health](https://s3.amazonaws.com/www.homehealthcareagencies.com/images/uploaded/6397.large.jpg)
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". The cookie is used to store the user consent for the cookies in the category "Analytics". These cookies ensure basic functionalities and security features of the website, anonymously. Necessary cookies are absolutely essential for the website to function properly.
![Uuid generator online](https://loka.nahovitsyn.com/212.jpg)